ANIP Stock: Price, Earnings History and SEC Filings
ANI Pharmaceuticals, Inc. (ANIP) last traded at $72.00, down 1.59% on the latest session and down 0.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $1.82 against an analyst estimate of $1.67, a beat of 9.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ANIP earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 7, 2026 | $1.82 | $1.67 | +8.98% |
| Mar 2026 | May 8, 2026 | $1.68 | $0.96 | +75.00% |
| Dec 2025 | Feb 27, 2026 | $1.98 | $1.62 | +22.22% |
| Sep 2025 | Nov 7, 2025 | $1.64 | $1.37 | +19.71% |
ANIP beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How ANIP reacts to earnings
Across its last 8 earnings releases, ANIP moved 4.3% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-07 | Before open | -5.30% |
| 2026-05-08 | Before open | -2.44% |
| 2026-02-27 | Before open | -4.21% |
| 2026-01-12 | After close | -2.45% |
| 2025-11-10 | Before open | -1.66% |
| 2025-11-07 | Before open | +0.22% |
| 2025-09-08 | Before open | -0.16% |
| 2025-08-08 | Before open | +18.07% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ANIP financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $883M | $78M | $171M | 8.9% | $3.32 |
| 2024 | $614M | -$19M | $48M | -3.0% | $-1.04 |
| 2023 | $487M | $19M | $110M | 3.9% | $0.85 |
| 2022 | $316M | -$48M | -$40M | -15.1% | $-3.05 |
| 2021 | $216M | -$43M | $765000 | -19.7% | $-3.40 |
| 2020 | $208M | -$23M | $9M | -10.8% | $-1.88 |
| 2019 | $207M | $6M | $39M | 3.0% | $0.50 |
| 2018 | $202M | $15M | $61M | 7.7% | $1.30 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ANIP
- 8-K · Aug 24, 2026Officer or director change, Financial statements and exhibits
- 10-Q · Aug 7, 2026
- 8-K · Aug 7, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · May 21, 2026Officer or director change, Shareholder vote, Financial statements and exhibits
- 8-K · May 13, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 8, 2026
- 8-K · May 8, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 9, 2026
- 8-K · Apr 7, 2026Financial statements and exhibits
- 8-K · Mar 3, 2026Regulation FD disclosure, Financial statements and exhibits
Insider filing activity
ANIP insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ANIP news
- NovoCure (NVCR) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- 3 market-beating stocks for long-term investorsOct 29, 2026 · finance.yahoo.com
- ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ETOct 23, 2026 · finance.yahoo.com
- ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release CapsulesOct 19, 2026 · finance.yahoo.com
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. (ANIP) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.